Cell Reports (Nov 2021)
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug
- Junfeng Bi,
- Atif Khan,
- Jun Tang,
- Aaron M. Armando,
- Sihan Wu,
- Wei Zhang,
- Ryan C. Gimple,
- Alex Reed,
- Hui Jing,
- Tomoyuki Koga,
- Ivy Tsz-Lo Wong,
- Yuchao Gu,
- Shunichiro Miki,
- Huijun Yang,
- Briana Prager,
- Ellis J. Curtis,
- Derek A. Wainwright,
- Frank B. Furnari,
- Jeremy N. Rich,
- Timothy F. Cloughesy,
- Harley I. Kornblum,
- Oswald Quehenberger,
- Andrey Rzhetsky,
- Benjamin F. Cravatt,
- Paul S. Mischel
Affiliations
- Junfeng Bi
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; ChEM-H, Stanford University, Stanford, CA, USA; Corresponding author
- Atif Khan
- Department of Medicine, Institute for Genomics and Systems Biology, University of Chicago, Chicago, IL, USA
- Jun Tang
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; ChEM-H, Stanford University, Stanford, CA, USA
- Aaron M. Armando
- Department of Pharmacology, UCSD School of Medicine, La Jolla, CA, USA
- Sihan Wu
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; ChEM-H, Stanford University, Stanford, CA, USA; Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA
- Wei Zhang
- Department of Medicine, UCSD School of Medicine, La Jolla, CA, USA
- Ryan C. Gimple
- Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA
- Alex Reed
- Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA
- Hui Jing
- Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA
- Tomoyuki Koga
- Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA, USA; Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA
- Ivy Tsz-Lo Wong
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; ChEM-H, Stanford University, Stanford, CA, USA
- Yuchao Gu
- Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
- Shunichiro Miki
- Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA, USA
- Huijun Yang
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; ChEM-H, Stanford University, Stanford, CA, USA
- Briana Prager
- Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA
- Ellis J. Curtis
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; ChEM-H, Stanford University, Stanford, CA, USA; Department of Medicine, UCSD School of Medicine, La Jolla, CA, USA
- Derek A. Wainwright
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Frank B. Furnari
- Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA, USA; Department of Pathology, UCSD School of Medicine, La Jolla, CA, USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA, USA
- Jeremy N. Rich
- Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA
- Timothy F. Cloughesy
- Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, CA, USA
- Harley I. Kornblum
- Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, CA, USA
- Oswald Quehenberger
- Department of Pharmacology, UCSD School of Medicine, La Jolla, CA, USA
- Andrey Rzhetsky
- Department of Medicine, Institute for Genomics and Systems Biology, University of Chicago, Chicago, IL, USA; Department of Human Genetics, Institute for Genomics and Systems Biology, University of Chicago, Chicago, IL, USA
- Benjamin F. Cravatt
- Department of Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA
- Paul S. Mischel
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; ChEM-H, Stanford University, Stanford, CA, USA; Corresponding author
- Journal volume & issue
-
Vol. 37,
no. 5
p. 109957
Abstract
Summary: The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible. Here, we identify sphingomyelin phosphodiesterase 1 (SMPD1), an enzyme that regulates the conversion of sphingomyelin to ceramide, as an actionable drug target in GBM. We show that the highly brain-penetrant antidepressant fluoxetine potently inhibits SMPD1 activity, killing GBMs, through inhibition of epidermal growth factor receptor (EGFR) signaling and via activation of lysosomal stress. Combining fluoxetine with temozolomide, a standard of care for GBM, causes massive increases in GBM cell death and complete tumor regression in mice. Incorporation of real-world evidence from electronic medical records from insurance databases reveals significantly increased survival in GBM patients treated with fluoxetine, which was not seen in patients treated with other selective serotonin reuptake inhibitor (SSRI) antidepressants. These results nominate the repurposing of fluoxetine as a potentially safe and promising therapy for patients with GBM and suggest prospective randomized clinical trials.
